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Advances in serologic assays for Cryptosporidium parvum have made
serology an attractive surveillance tool. The sensitivity, specificity, and pre-
dictive value of these new assays for surveillance of immunocompromised
populations, however, have not been reported. Using stored serum speci-
mens collected for the San Francisco Men's Health Study, we conducted a
case-control study with 11 clinically confirmed cases of cryptosporidiosis.
Based on assays using a 27-kDa antigen (CP23), the serum specimens
from cases had a median response immunoglobulin (Ig) G level following
clinical diagnosis (1,334) and a net response (433, change in IgG level from
baseline) that were significantly higher than their respective control values
(329 and -32, Wilcoxon p value = 0.01). Receiver operator curves estimated
a cutoff of 625 U as the optimal sensitivity (0.86 [0.37, 1.0]) and specificity
(0.86 [0.37, 1.0]) for predicting Cryptosporidium infection. These data sug-
gest that the enzyme-linked immunosorbent assay technique can be an
effective epidemiologic tool to monitor Cryptosporidium infection in immuno-
compromised populations. 
Cryptosporidium oocysts are regularly detected in
treated and untreated water and have been associated with
both food- and waterborne outbreaks (1,2). Of particular con-
cern are immunocompromised persons, among whom HIV-
infected persons represent a large group at risk for
cryptosporidiosis (3-8). Cryptosporidiosis in HIV-infected
persons may be chronic and is associated with substantial
mortality. Recent evidence suggests that, in addition to their
protracted course of infection, HIV-infected persons may be
at higher risk for acquiring infection (9). The introduction of
highly active antiretroviral therapy has decreased the inci-
dence of cryptosporidiosis among HIV-positive persons (10),
but there are no data to suggest that the incidence of expo-
sure has been reduced.
In part because of limited surveillance tools, much is
still unknown about the natural history of cryptosporidiosis
(11). To confirm Cryptosporidium infection, stool specimens
are often examined by microscopy. For epidemiologic studies,
this method is problematic because of the short duration of
oocyst excretion, the poor sensitivity of the procedure (12),
and the amount of laboratory personnel time needed. More-
over, many physicians are unaware of cryptosporidiosis (13).
Therefore, since most laboratories examine stools
specifically for Cryptosporidium only on physician request
(14), cryptosporidiosis is generally underdiagnosed.
Serologic assays provide an alternative to parasitologic
methods for monitoring Cryptosporidium infections.
Although many previous studies have used crude extracts of
disrupted oocysts as the antigen in an enzyme-linked immu-
nosorbent assay (ELISA), assays based on detection of anti-
body responses to specific Cryptosporidium antigens by
immunoblot are more sensitive and specific. When the
immunoblot is used, persons exposed to Cryptosporidium in
outbreak settings have characteristic responses to 27-kDa
(immunoglobulin [Ig] G) and 17-kDa (IgA, IgG) antigens,
which are found on the surface of sporozoites, the infective
stage of the parasite. In studies of volunteers exposed to
C.parvum, antibodies directed against these antigens were
correlated with lower levels of oocyst excretion and with pro-
tection from symptomatic infection (15).
From previous studies measuring responses to crude
oocyst antigen, it is clear that HIV-positive persons can
make antibody responses to C. parvum (16); however, these
responses have not been assessed by the newer assay for-
mats. Consequently, little is known about the ability of HIV-
positive persons to mount an immune response to defined
C.parvum antigens. The question remains whether HIV-
positive persons can mount an antibody response, and, if so,
whether the magnitude of the response is associated with
CD4 count. To address these issues, we examined 28 clini-
cally confirmed cases of cryptosporidiosis, assaying IgG
responses for the 11 cases in which we had blood samples
collected after the date of diagnosis.
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Methods
Study Population
The San Francisco Men’s Health Study (SFMHS) was a
prospective study of the epidemiology and natural history of
AIDS in a cohort of 1,034 single men between the age of 25
and 54 years (17). The subjects were recruited by multistage
probability sampling and followed from 1984 through 1992.
The men were followed every 6 months with an interview, a
complete physical examination, and collection of clinical
specimens. Serum banks have been maintained in liquid
nitrogen since the beginning of the study. The institutional
review boards of the University of California, Berkeley, and
the Centers for Disease Control and Prevention approved
this project.
A person was reported to have had cryptosporidiosis if
he answered yes to the following question: “Since we last
interviewed you (6 months ago), did a doctor or other medical
practitioner tell you that you had cryptosporidiosis?” All
diagnoses were based on finding oocysts in stool samples.
Although we have no information on the illness status of
these cases, it is unlikely that stool samples would have been
collected for asymptomatic patients.
Records from the SFMHS were reviewed to identify per-
sons diagnosed with C. parvum infection. Of 28, 11 had at
least one serum sample collected after the date of diagnosis
of cryptosporidiosis. To analyze antibody decay, we excluded
persons with chronic cryptosporidiosis infection by excluding
those with a CD4 count <200, on the assumption that these
persons were at high risk for chronic cryptosporidiosis infec-
tion.
A control was defined as a person who 1) never had a
clinical diagnosis of cryptosporidiosis while under observa-
tion; 2) had a serum sample available within 3 months
(based on the date of the blood sample used to measure the
IgG response after diagnosis of cryptosporidiosis for a
matched case); and 3) had a CD4 count at this blood sample
date that was within 50 cells/µL of the case CD4 count. For
each case, two controls were randomly selected from all pos-
sible controls who met these three criteria.
Rationale for IgG Analysis
Assays based on the detection of IgA, to date, lack sensi-
tivity. IgM results with crude-antigen ELISAs and with
immunoblot have suggested that IgM is directed primarily
at carbohydrate epitopes. IgM assays thus tend to be charac-
terized by low signal-to-noise ratios and poor specificity. In
addition, IgM responses tend to be short-lived, exacerbating
issues related to the sensitivity of detection of antibody
responses.
ELISA
Antibody assays used either a recombinant Cp23 protein
or a partially purified native antigen fraction isolated from
oocysts by Triton X-114 detergent extraction and were per-
formed as described (18). Briefly, antigens were diluted in
0.1 M Na HCO3 buffer at pH 9.6 to concentrations of 0.2 µg/
mL (recombinant Cp23) or 0.28 µg/mL (Triton X-114-
extracted antigen) and were used to sensitize 96-well plates
overnight at 4°C (50 µL/well; Immunlon 2, Dynatech Indus-
tries, McLean, VA). Plates were blocked with phosphate-
buffered saline (PBS) (0.85% NaCl and 10 mM Na2PO4 at
pH 7.2) containing 0.3% Tween 20 for 1 hour at 4°C, then
washed four times with 0.05% Tween 20/PBS. Unknown sera
were diluted 1:50 in 0.05% Tween 20/PBS and loaded in
duplicate (50 µL/well). Four blank wells (buffer only), dupli-
cate wells containing three positive control sera, and dupli-
cate wells containing four negative sera were included on
each plate. A twofold serial dilution (1:50 to 1:12,800) of a
strong positive control was also included on each plate to
generate a standard curve. The plates were incubated for 2
hours at room temperature. Bound antibodies were quanti-
fied by using a biotinylated mouse monoclonal antibody
against human IgG (1:1,000 in 0.05% Tween 20/ PBS) (clone
HP6017; Zymed Laboratories, South San Francisco, CA) and
alkaline phosphatase-labeled streptavidin (1:500 in 0.05%
Tween 20/PBS) (Life Technologies, Rockville, MD) with p-
nitrophenylphosphate substrate (Sigma Chemical Co., St.
Louis, MO) as described (18). Absorbances at 405 nm were
measured with a Molecular Devices UVmax kinetic micro-
plate reader (Sunnyvale, CA). Antibody levels of unknown
samples were assigned a unit value based on the 9-point pos-
itive control standard curve with a four parameter curve fit.
The 1:50 dilution of the positive control serum was arbi-
trarily assigned a value of 6,400 U. Arbitrary unit values
were expressed per microliter of serum.
Statistical Analysis
IgG response measures were reported in arbitrary units
based on the standard curve described above. These anti-
body responses were not normally distributed; consequently,
the responses of the cases and controls were compared by
using the Wilcoxon rank sum test. Least squares regression
was used to examine the temporal degradation of antibody
responses. A receiver operator curve (ROC) was constructed
to examine the sensitivity and specificity of different cutoff
values (joint confidence intervals were based on exact meth-
ods).
Results
Table 1 summarizes antibody responses of cases and
controls. When the CP23 antigen was used, the median IgG
value of the sample collected after the diagnosis of cryptospo-
ridiosis (1,334 U for the cases) was significantly different
from the control samples collected at the same time (329 U)
(p<0.05). The median net increase in IgG levels between the
serum samples collected before and after the diagnosis date
for cases (433) was also significantly different from that for
controls (-32) (p<0.05). The time interval between date of
diagnosis of cryptosporidiosis and date of the blood sample
was 44 to 369 days. After diagnosis with cryptosporidiosis,
the median IgG value, when TX17 antigen was used, was not
significantly different for cases (140 U) and controls (56 U);
however, the median increase in IgG levels between the
blood samples before and after the diagnosis date for the
cases (71 U) was significantly different from that for controls
(-1 U) (p<0.05). IgG responses of cases and controls at enroll-
ment into the SFMHS in 1984 were not significantly differ-
ent, suggesting that in general IgG levels of cases were not
distinguishable from those of controls when not associated
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with a cryptosporidiosis diagnosis. There were some notable
exceptions, e.g., one control had IgG levels consistently
above 1,000 in four measurements from 1984 to 1992.
Detailed information on cases and controls is shown in
Table2.
Next, we estimated the optimal cutoff or threshold value
to be used as a predictor for whether an IgG response per-
mitted classification of the subject as a case or a control.
Based on the seven cases that had an IgG measurement
within 200 days of the diagnosis date, Figure 1 shows an
ROC curve (plot of false positives vs. true positives). A
threshold of 625 U was estimated to maximize both the sen-
sitivity (0.86 [0.37, 1.0]) and specificity (0.86 [0.37, 1.0]) of
the data; this threshold was chosen as the value on the curve
closest to the upper lefthand corner of the graph. We
recalculated the ROC curve using the five cases that had an
IgG measurement within 100 days of the diagnosis date, as
well as the 10 cases with measurements within 300 days.
Both analyses resulted in the same estimate for the optimal
cutoff value of 625. 
The kinetics of the antibody response to the CP23 anti-
gen for each of the 11 cases are shown in Figure 2. Antibody
responses were plotted relative to the cryptosporidiosis diag-
nosis for the 11 cases (time 0 represents the date of diagno-
sis). The plots were divided into three panels based on the
625-U threshold estimate. The top panel contains the five
cases that had an IgG level <625 before and >625 after clini-
cal diagnosis (Cases 1,2,3,4, and 7). All these cases had 3- to
20-fold increases in IgG levels. The middle panel contains
the responses that had values >625 before and after clinical
diagnosis (Cases 5,6,8, and 9). More detailed observations of
these four cases revealed 1) data for Cases 5 and 9 were









Cases Controls Cases Controls Cases Controls Cases Controls
Mean 2,784 c 414 2,117 c -17 1,594 85 1,531 5
Max 12,224 973 11,247 157 9,264 217 9,239 69
Min 102 178 -866 -144 36 41 -5 -47
Median 1,334d 329 433 d -32 140 56 71d -1
S.D. 3,560 237 3,531 84 2,880 53 2,884 36
N 11 22 11 22 11 22 11 22
aIgG response after the date of clinical cryptosporidiosis diagnosis.
bDifference in IgG response between a sample taken before and after date of cryptosporidiosis diagnosis.
cCase value is significantly different from control value (p<0.05).
dCase value is significantly different from control value (p<0.01).
IgG = immunoglobulin G; TX17 = Triton antigen; SD = standard deviation.
Table 2. Serologic response from enzyme-linked immunosorbent assay, using the CP23 antigen, of the 11 cases that had blood samples after the






IgG (CD4/days)a DIgG response b IgG peak valuec DIgG response d
1 204 (786/102) 637(500/108) 433 178 15
2 118 (259/100) 2,376 (186/115) 2,258 463 36
3 977 (96/134) 12,224(18/216) 11,247 233 -70
4 342 (248/138) 5,724 (440/44) 5,382 263 -22
5 1,084 (1,003/907) 1,309 (M/47) 225 359 79
6 705 (296/71)  672 (487/369) -33 414 -80
7 611 (148/202) 3,911 (52/293) 3,300 605 -85
8 2,200 (39/114) 1,334 (33/73) -866 973 -32
9 891 (159/363)  2,108 (26/34) 1,217 292 -35
10 105 (108/79) 224 (13/92) 119 187 -144
11 102 (435/132)  102 (472/238) 0 597 157
aCD4 count and days from cryptosporidiosis diagnosis date.
bDifference in IgG response between a sample taken before and after date of cryptosporidiosis diagnosis.
cAverage of the two controls (CD4 count and sample date were matched to the respective cases).
dAverage difference in IgG response between the two controls.
M = missing data; IgG = immunoglobulin G; dx = diagnosis.
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insufficient to assess the antibody response to infection since
the last serum samples collected before diagnosis date were
3 and 1 years before infection, respectively; 2) the lack of
response from Case 6 may be because the first available
sample after diagnosis was obtained 1 year after diagnosis;
and 3) a twofold increase in antibody occurred for Case 8
before the clinical diagnosis date. The bottom panel presents
the two cases that remained below 625 U. Case 11 had no
increase in IgG levels, and Case 10 had a twofold increase
but remained below the threshold. 
To determine the duration of antibody response, we ana-
lyzed the relationship between antibody level
and the time interval between infection and
sample collection. To reduce the likelihood
that chronic infections would interfere with
the analysis, we restricted our analysis to
persons with CD4 counts >200. Although
sample numbers were small (n = 6), this pre-
liminary analysis suggests that CP23
responses decline to baseline approximately
300 days after an initial response of 3,200 U.
Further studies will be necessary to confirm
this conclusion.
Discussion
Study of the natural history of cryptospo-
ridiosis has been limited because of the diffi-
culty of collecting data during the acute
phase of the disease. Often, incidence rates
are too low to make prospective studies feasi-
ble. The blood bank from the SFMHS pro-
vided a unique opportunity to study the serologic
responsiveness of a cohort of HIV-positive homosexual men
clinically confirmed with cryptosporidiosis. Two features of
this database make it well suited for a serologic study of
cryptosporidiosis: 1) blood was sampled regularly at 6-month
intervals from 1984 to 1994, and yearly from 1994 to 1997;
and 2) reporting of cryptosporidiosis increased because it is
an AIDS-defining condition. We identified 28 clinically diag-
nosed cases; however, only 11 cases had blood samples both
before and after the diagnosis date. To a large extent this
was because many of the patients died from Cryptosporid-
ium infection. Even when restricted to the 11 cases of
cryptosporidiosis with specimens available after diagnosis,
the analysis clearly demonstrated the ability of the ELISA
using CP23 antigen to discriminate cases from matched con-
trols. These results suggest that the ELISA is a viable
approach to identifying recently infected HIV-positive per-
sons. If augmented with data on incidence of diarrhea, this
approach could be used to provide valuable estimates of the
level of asymptomatic Cryptosporidium infection. 
One concern with a seroprevalence study in an HIV-pos-
itive cohort such as homosexual men in San Francisco is that
Cryptosporidium exposure might be ubiquitous and chronic.
Most of the controls, however, had IgG levels that were sig-
nificantly below case levels, suggesting that antibody levels
are not continuously high in HIV-positive persons. In addi-
tion, the IgG responses of cases and controls at enrollment
into the SFMHS in 1984 were not significantly different,
suggesting that cases were not inherently more responsive to
C. parvum than controls. The fact that the IgG response of
the cases after infection differed from that of controls sug-
gests that this cohort either had a low frequency of exposure
or a relatively rapid decay of the antibody response. Our pre-
liminary analysis suggests that a response would decay to
control levels after approximately 1 year. This result is con-
sistent with those of other studies (19).
Two limitations to this population-level estimate of IgG
degradation are 1) our sample size was small, and 2) chronic
infection and multiple exposures may interfere with the nat-
ural decay of the IgG response. Because of this small sample
size, we were not able to address some potentially interest-
ing and relevant issues, such as the relationship between
Figure 1. Receiver operator curve for various immunoglobulin G (IgG) cutoff values,
based on the seven cases that had a blood sample within 200 days of their diagnosis
date.
Figure 2. Temporal immunoglobulin G (IgG) response of the 11
cases, grouped by high IgG responders (Cases 1,2,3,4,7), medium
responders (Cases 5,6,8,9), and low responders (Cases 10,11). Time
zero for each plot is the time of clinical diagnosis.
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serologic response and CD4 count. Since this study provides
us with criteria for Cryptosporidium exposure, our future
studies will not be limited to clinically confirmed cases and
will therefore be able to obtain greater sample sizes. 
With regard to the second limitation, we assumed that
chronic infection was a potential problem and therefore
excluded from the analyses subjects with a CD4 count <200/
µL—that is, low CD4 count was used as a surrogate indica-
tor for high risk for chronic infection (9,20). Although this
was an indirect method of removing chronically infected
cases, it provided us with a result that was consistent with
previous studies of the kinetics of the antibody response to
other antigens. Specifically, when an infection is not chronic,
antibody levels decay over time.
The results of our study must also be interpreted in light
of the fact that there was no information on the magnitude
and timing of the exposure to C. parvum nor on prior expo-
sures to C. parvum for these cases. These complications may
explain why we have three patterns of responses (Figure 2):
1) The strong responders (Cases 1,2,3,4,7), who had low ini-
tial levels of IgG and who presumably had no or limited prior
exposure; 2) The intermediate responders (Cases
5,6,8,9),who had initial antibody levels consistent with prior
exposure or possible chronic infection. Three of these cases
(5,8, and 9) had CD4 counts <100, suggesting that the pres-
ence of a chronic infection was possible; and 3) The nonre-
sponders (Cases 10 and 11), who never produced levels above
control values. The reason for this last pattern of response is
not clear. Knowledge of exposure dose may help explain
some of these differences. There is no evidence from these
data that the level of CD4 count explained the magnitude of
the humoral response. For example, Case 3, with a CD4
count of 96, had the strongest IgG response; Case 1, with a
CD4 count of 500, had a relatively weak response. Factors
responsible for determining the magnitude of the antibody
response in infected persons have not been defined.
The Triton antigen (TX17) in this study was less useful
than the CP23 antigen in distinguishing cases from controls.
Although the TX17 could make this distinction based on the
net antibody response to infection, these responses were rela-
tively low. Assays based on use of the TX17 antigen have per-
formed well in previous studies of outbreak populations. A
possible reason for our results could be that the antibody
response to this antigen is shorter lived. Alternatively,
immunodeficient persons may not respond fully to this anti-
gen. Neither explanation is well supported by the data. Cases
5 and 9 had low responses, even though blood samples were
collected within 47 days of diagnosis, at a time when peak
responses would be expected. Likewise, the second explana-
tion is not supported by the data since one of the three strong
responders was Case 3, who had a CD4 count of 96. 
Results from this serologic study suggest that surveil-
lance activities could be designed using a serologic test based
on the CP23 antigen to estimate the number of recent infec-
tions of Cryptosporidium. Two pieces of information required
before this test can be used are the definition of the optimal
threshold IgG value that would define an infection event and
the definition of a recent infection. ROC (Figure 1) provides
both a method to optimize the choice of a threshold value to
identify a case, based on the desired specificity and sensitiv-
ity, and a definition of recent infection, based on the decay of
the antibody response. ROC analyses suggest that a level
>625 U indicates an infection occurred within the past 100 to
300 days.
These results suggest that CP23 has important utility in
the study of the epidemiology and natural history of
cryptosporidiosis in HIV-infected populations. The value of
CP23 in studying other potentially immunocompromised
populations (such as oncology patients, children, and the eld-
erly) deserves investigation.
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